Cost-effectiveness of sevelamer in the treatment of hyperphosphatemia associated with chronic kidney disease in Mexico

被引：0
|
作者：
Idrovo, J. [1 ]
Rivas, R. [1 ]
Zapata, L. [1 ]
机构：
[1] Guia Mark, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70949-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A301 / A301
页数：1
相关论文
共 50 条
  • [31] THE COST-EFFECTIVENESS OF PATIROMER FOR THE TREATMENT OF HYPERKALAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HEART FAILURE IN THE UK
    Ward, T.
    Baxter, G.
    Serna, Ramirez de Arellano A.
    VALUE IN HEALTH, 2022, 25 (01) : S43 - S43
  • [32] Cost-effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes
    Nguyen, Bao-Ngoc
    Mital, Shweta
    Bugden, Shawn
    Nguyen, Hai V.
    DIABETES OBESITY & METABOLISM, 2023, 25 (10): : 3030 - 3039
  • [33] THE COST-EFFECTIVENESS OF PATIROMER FOR THE TREATMENT OF HYPERKALAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HEART FAILURE IN IRELAND
    Ward, T.
    Serna, Ramirez de Arellano A.
    Quinn, C.
    VALUE IN HEALTH, 2022, 25 (01) : S95 - S95
  • [34] Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease
    Erickson, Kevin F.
    Japa, Sohan
    Owens, Douglas K.
    Chertow, Glenn M.
    Garber, Alan M.
    Goldhaber-Fiebert, Jeremy D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (12) : 1250 - 1258
  • [35] Cost-effectiveness of chronic kidney disease mass screening test in Japan
    Kondo, Masahide
    Yamagata, Kunihiro
    Hoshi, Shu-Ling
    Saito, Chie
    Asahi, Koichi
    Moriyama, Toshiki
    Tsuruya, Kazuhiko
    Yoshida, Hideaki
    Iseki, Kunitoshi
    Watanabe, Tsuyoshi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2012, 16 (02) : 279 - 291
  • [36] Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease
    Tisdale, Rebecca L.
    Cusick, Marika M.
    Aluri, Kelly Zhang
    Handley, Thomas J.
    Joyner, Alice Kate Cummings
    Salomon, Joshua A.
    Chertow, Glenn M.
    Goldhaber-Fiebert, Jeremy D.
    Owens, Douglas K.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2022, 37 (13) : 3380 - 3387
  • [37] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN CHRONIC KIDNEY DISEASE (CKD) MANAGEMENT IN THE UK
    Ramos, M.
    Gerlier, L.
    Uster, A.
    Aguirre, A. R.
    Muttram, L.
    Frankel, A. H.
    Lamotte, M.
    VALUE IN HEALTH, 2023, 26 (12) : S131 - S132
  • [38] Cost-effectiveness of chronic kidney disease mass screening test in Japan
    Masahide Kondo
    Kunihiro Yamagata
    Shu-Ling Hoshi
    Chie Saito
    Koichi Asahi
    Toshiki Moriyama
    Kazuhiko Tsuruya
    Hideaki Yoshida
    Kunitoshi Iseki
    Tsuyoshi Watanabe
    Clinical and Experimental Nephrology, 2012, 16 : 279 - 291
  • [39] Cost-effectiveness analysis of dapagliflozin for people with chronic kidney disease in Malaysia
    Lim, Soo Kun
    Lee, Shaun Wen Huey
    PLOS ONE, 2024, 19 (03):
  • [40] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN ADULT PATIENTS WITH CHRONIC KIDNEY DISEASE IN THE NETHERLANDS
    Fens, T.
    Weersma, M.
    Postma, M. J.
    Boersma, C.
    de Jong, L.
    VALUE IN HEALTH, 2023, 26 (12) : S132 - S132
12345